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Background: The idiopathic inflammatory myopathies represent a group of autoimmune diseases that are
characterized by lymphocyte infiltration of muscle and muscle weakness. Insulin-like 6 (Insl6) is a poorly characterized
member of the insulin-like/relaxin family of secreted proteins, whose expression is upregulated upon acute muscle
injury.
Methods: In this study, we employed Insl6 gain or loss of function mice to investigate the role of Insl6 in a T
cell-mediated model of experimental autoimmune myositis (EAM). EAM models in rodents have involved
immunization with human myosin-binding protein C with complete Freund’s adjuvant (CFA) emulsions and
pertussis toxin.
Results: Insl6-deficiency in mice led to a worsened myositis phenotype including increased infiltration of CD4 and
CD8 T cells and the elevated expression of inflammatory cytokines. Insl6-deficient mice show significant motor
function impairment when tested with treadmill or Rotarod devices. Conversely, muscle-specific overexpression of
Insl6 protected against the development of myositis as indicated by reduced lymphocyte infiltration in muscle,
diminished inflammatory cytokine expression and improved motor function. The improvement in myositis by Insl6
could also be demonstrated by acute hydrodynamic delivery of a plasmid encoding murine Insl6. In cultured cells,
Insl6 inhibits Jurkat cell proliferation and activation in response to phytohemagglutinin/phorbol 12-myristate
13-acetate stimulation. Insl6 transcript expression in muscle was reduced in a cohort of dermatomyositis and
polymyositis patients.
Conclusions: These data suggest that Insl6 may have utility for the treatment of myositis, a condition for which
few treatment options exist.
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Idiopathic inflammatory myositis is a category of auto-
immune muscle disorders that include polymyositis,
dermatomyositis and inclusion body myositis. Features
common to all of the subtypes include muscle weakness,
histological evidence of muscle inflammation and elevated
levels of creatine kinase. However, each subset also has
unique clinical, immunopathologic and histologic criteria
[1]. Dermatomyositis is a vascular endothelial lesion asso-
ciated with perimysial inflammation and perifascicular* Correspondence: kxwalsh@bu.edu
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unless otherwise stated.muscle fiber atrophy, whereas polymyositis is associated
with injury to muscle fibers by aggressive immune cells
which predominantly infiltrate the endomysium [2].
Macrophages, dendritic cells, and T cells are promin-
ently present in muscle of the different myositis sub-
groups. In dermatomyositis, large numbers of helper T
cells (CD4 T cells) are found within the perimysial,
often perivascular areas. In polymyositis, activated
cytotoxic T cells (CD8 T cells) surround and invade
non-necrotic muscle fibers, while helper T cells are
found at more distant parts of the infiltrates [3]. These
inflammatory muscle diseases are rare and there are
few effective treatment strategies for these patients [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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after myofiber damage [5,6]. Muscle damage stimulates
massive infiltration of immune cells into the injury site,
including neutrophils, macrophages, and T cells. These
cells function in the phagocytosis of necrotic muscle fi-
bers, express pro-inflammatory cytokines and participate
in satellite cell activation [7]. We have previously dem-
onstrated that Insl6 has muscle regenerative and anti-
inflammatory activities in a cardiotoxin-induced model
of severe muscle injury when expressed using an engi-
neered adenovirus vector [8]. We therefore sought to ex-
tend these studies and explore the utility of Insl6 in the
setting of inflammatory muscle injury using a rodent
model of myositis.
In the current study, we employed Insl6 gain or loss
of function mice to investigate the role of Insl6 in a T
cell-mediated model of experimental autoimmune myo-
sitis (EAM). EAM models in rodents have involved
immunization with native myosin-binding protein C
with complete Freund’s adjuvant (CFA) emulsions and
pertussis toxin (PT) [9,10]. In murine EAM, the infiltra-
tion of CD4 and CD8 T cells is observed, similar to
what is seen in human PM and DM [11]. Of interest,
depletion of both CD4 and CD8 T cells suppresses the
myositis phenotype in this model [11]. Using this model,
we find that Insl6-deficiency led to greater muscle dam-
age, increased inflammation and reduced motor function
in the murine model of EAM. Conversely, Insl6 overex-




RPMI-1640 medium, DMEM, FBS, penicillin-streptomycin
mixture, and Alexafluor 488® goat anti-rabbit IgG antibody
were obtained from Invitrogen (Carlsbad, CA). Anti-CD4
and anti-CD8 antibodies conjugated with eFluor® 650NC
were purchased from eBioscience. Fluorescein isothio-
cyanate (FITC)-conjugated anti-CD4 antibody was ob-
tained from BD Biosciences (San Jose, CA). Freund’s
complete adjuvant (CFA), PT, phytohemagglutinin (PHA),
phorbol 12-myristate 13-acetate (PMA), protease inhibitor
cocktail, RIPA buffer, and anti-laminin antibody were pur-
chased from Sigma (St. Louis, MO). Tubulin-α antibody
and horseradish peroxidase (HRP)-conjugated anti-rabbit
antibodies were purchased from Cell Signaling (Danvers,
MA). 3H-thymidine was purchased from PerkinElmer
(Waltham, MA).
Mice
MCK-Insl6-TG mice in a C57BL/6 background were
generated as previously described [8]. These mice ex-
press murine Insl6 cDNA from a 4.8 kb pair fragment of
the murine creatine kinase M promoter. Insl6-deficientmice were described previously [12]. In Insl6-deficient
mice, exon 1 of Insl6 genomic DNA is replaced by the
PGK-neomycin(Neo) selection cassette. Insl6+/− heterozy-
gous female and male pairs were used for breeding, and the
offspring littermates (Insl6+/+ and Insl6−/−) were used for
experiments. In some instances, C57BL/6 mice were pur-
chased from Charles River Laboratories (Cambridge, MA).
Mice were housed on a fixed 12-hour light/dark cycle and
fed a normal chow diet (Teklad Global 18% protein rodent
diet, 2018, Harlan Teklad). Study protocols were approved
by the Institutional Animal Care and Use Committee at
Boston University.
Fc tagged Insl6 plasmid
The human IgG1 Fc was fused at the N-terminus of full-
length mouse Insl6. In brief, mouse Insl6 cDNA was PCR
amplified and cloned into pLEV113 mammalian expres-
sion vector (LakePharma, Belmont, CA) downstream of
an in-frame human IgG1 Fc domain and a secretion signal
peptide. This plasmid was used to perform hydrodynamic
injection.
Recombinant human skeletal muscle myosin-binding C
protein
The recombinant skeletal muscle myosin-binding C pro-
tein was prepared using a prokaryotic expression pro-
cedure. A cDNA fragment of human fast-type skeletal
muscle C protein was amplified from human skeletal
muscle cDNA using PCR. Primers sequences were previ-
ously described by Sugihara et al. [11]. The cDNA frag-
ment was sub-cloned into Qiagen pQE30 expression
vector and the plasmid was maintained and amplified in
E. coli XL-1 Blue strain. E. coli M15 (pREP4) contained
in the QIAexpressionist™ was used to prepare the re-
combinant C protein according to the manufacturer’s
protocol (Qiagen, Valencia, CA). The soluble recombin-
ant protein was dialyzed against 0.5 M arginine, 2 mM
reduced glutathione, and 0.2 mM oxidized glutathione
in PBS, pH 7.4. Endotoxin removal was performed with
Detoxi-Gel. The molecular weight of C protein is ap-
proximately 35 kDa.
Chronic inflammatory myositis model
Female mice, eight to ten weeks old, were immunized
intradermally with 600 μg of the C protein emulsified in
CFA containing 100 μg of heat-killed Mycobacterium
butyricum (Sigma, St. Louis, MO). The immunogens
were injected subcutaneously at multiple sites around
the torso or on the feet, and 2 μg of PT in PBS was
injected intraperitoneally at the same time.
Cardiotoxin-induced muscle injury model
A 10 μM solution of cardiotoxin (CTX) or equal volume
of PBS was injected into the tibialis anterior (TA) muscle
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scribed previously [8]. The needle was inserted parallel
to the muscle fiber longitude until reaching the tendon
which inserts into the knee and then slowly withdrawn
while simultaneously injecting the CTX solution in its
path.
Hydrodynamic delivery of plasmid DNA
Mice were pre-warmed by heat lamp for 20 minutes,
and a plastic restrainer was used to keep mice in position
during injection. Ten micrograms of Insl6-Fc or control
vectors were dissolved in a large volume of saline (80 μl/g
body weight) and injected quickly within 8 seconds via the
tail vein [13].
Rotarod test
Muscle function was evaluated with a Rotarod device.
The test was performed on each mouse by measuring
the running time until the mouse fell off the rod. Mice
were initially trained to acclimate them to the task, and
then tested two days thereafter. The turning speed was
set at 10 revolutions/minute for knockout (KO) mice
and their littermate controls, and at 20 revolutions/mi-
nute for transgenic (TG) mice and controls, to better
distinguish the differences between the genetically ma-
nipulated KO and TG strains of mice and control litter-
mates. The protocol was modified from published work
[14]. Each mouse was scored according to its time on
the rotating rod: score 1 corresponding to 0 to 30 seconds,
score 2 for 31 to 60 seconds, score 3 for 61 to 90 seconds,
and so on. A maximum score of 20 was recorded for mice
running more than 10 minutes.
Treadmill test
The treadmill test employs a moving belt (Columbus In-
struments, Columbus, OH). All mice were subjected to a
30 minute run on a horizontal treadmill at 12 m/minute,
twice per week before the experimental analysis [13]. To
assess running performance, the treadmill was initiated
with a start speed of six m/minute, and speed was in-
creased by two m/minute every five minutes for KO
mice and their littermate control mice. For TG mice and
littermate controls, a starting speed was ten m/minute,
and speed was increased by five m/minute every five
minutes. Different belt speeds were chosen to better
distinguish between the running performance of test
and control sets of mice when KO and TG groups were
analyzed. Electrical stimulation was applied to encour-
age the mice to run on the belt. The total running dis-
tance was recorded after mice elected not to run for a
period of 30 seconds. Study protocols were approved
by the Institutional Animal Care and Use Committee at
Boston University.Histological analysis of murine samples
Skeletal muscle tissues were embedded in OCT com-
pound and snap-frozen in liquid nitrogen. Serial cryostat
sections (8 μm) were fixed for 10 minutes in 10% formalin,
and were stained with H&E (Fisher Scientific, Pittsburgh,
PA) for histological analysis. The inflammatory lesion was
visualized using a × 40 objective. For immunofluorescence
staining, serial cryostat sections (8 μm) were fixed in cold
acetone and stained with eFluor® 650NC conjugated anti-
CD4 or CD8 antibody (1:100 dilution), and anti-laminin
primary antibodies (1:25 dilution). Alexafluor 488® goat
anti-rabbit IgG secondary antibody (1:200 dilution) was
used to visualize laminin expression. Fifteen randomly
chosen microscopic fields from three different sections in
each tissue block were examined for the presence of anti-
gen expressing cells.
Insl6 antibody production
Insl6 rabbit polyclonal antibody against peptides 1) VPAG
VSQKKGTHT, 2) QLQKKSTNKMNTF and 3) TKEEMA
VACLPFVDF was custom ordered from Thermo Fisher
Inc. (Pittsburgh, PA). The antibody was purified from anti-
serum by antigen specific affinity purification. Antiserum
was passed through a column containing resin beads con-
jugated to the immunogenic Insl6 peptides. Antibodies
were eluted using a pH gradient, collected in a neutraliz-
ing buffer and concentrated before use.
Western blotting
Skeletal muscle tissues were homogenized in radioimmu-
noprecipitation assay (RIPA) buffer which was supple-
mented with protease inhibitor cocktail. Equal amount of
proteins were loaded on 10% NuPAGE Gels (Invitrogen,
Carlsbad, CA) and run as instructed by the manufacturer.
The transfer to PVDF membranes was done under wet
conditions. Membranes were blocked in 5% skimmed milk
or BSA solution, and then incubated with primary anti-
bodies at 4°C overnight. Membranes were washed several
times in Tris-buffered saline with Tween (TBST) while
agitating, and then incubated with HRP-conjugated
anti-rabbit secondary antibodies at room temperature
for one hour. Chemiluminescent antigen expression was
captured on film by electrochemiluminescence (ECL)
using a Western Blotting Detection kit (GE Healthcare,
Buckinghamshire, UK.
Quantitative real-time PCR
cDNA was produced from total RNA using ThermoScript
RT-PCR Systems (Invitrogen, Carlsbad, CA). Transcript
levels were determined relative to the signal from 36B4,
and normalized to the mean value of samples from control
mice. Primers were purchased from Integrated DNA Tech-
nology (Coralville, IA). The following primer sequences were
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TTGTCTGTT-3′, R: 5′-AGGACTTTGCTCCTCCATCTC
GAA-3′); Neo (F: 5′-TGTCGATCAGGATGATCTGG-3′,
R: 5′-CCACCATGATATTCGGCAAG-3′); mouse CD8
(F: 5′-CTGTTTTCTGCCATGAGGGACACG-3′, R: GT
TCACTTTCTGAAGGACTGGCACG-3′); mouse CD4
(F: 5′-GCTGTCACAACTCCTAGCTGTCAC-3′, F: 5′-
CCTCTAATTAATACACCTTTGCCATGC-3′); mouse
TNF-α (F: 5′-ACAGAAAGCATGATCCGGGA-3′, R:
5′-TCTGGGCCATAGAACTGATG-3′); mouse IFN-γ
(F: 5′-CACGGCACAGTCATTGAAAG-3′, R: 5′-CAT
CCTTTTGCCAGTTCCTC-3′); mouse 36B4 (F: 5′-G
CTCCAAGGAGATGCAGCA-3′, R: CCGGATGTGA
GGCAGCAG-3′).Jurkat T cell proliferation assay
Jurkat cells obtained from the American Type Culture
Collection (Manassas, VA) were maintained in growth
medium (RPMI supplemented with 10% FBS). Cells were
transiently transfected with β-galactosidase (β-gal) or
murine Insl6 expression plasmids (pcDNA3, Invitrogen,
Carlsbad, CA) that employed the cytomegalovirus pro-
moter. Electroporation by Gene Pulser™ (BioRad, Hercules,
CA) was conducted at 250 V and 960 μF with time constant
of 24 to 30 seconds. Cell proliferation was assessed
by 3H-thymidine incorporation. Forty-eight hours after
transfection, cells were incubated with 3H-thymidine
(2.0 μCi/107 cells) for four hours. Cells were washed
twice with ice cold PBS and lysed with 10% sodium hy-
droxide. Cell lysates were suspended in liquid scintillation
buffer. The incorporation of radioactivity was determined
by liquid scintillation analyzer (TRI-CARB2900TR,
PerkinElmer, Waltham, MA). In related experiments,
C2C12 cells were incubated with Ad-Insl6 and Ad-β-gal
virus vectors at a multiplicity of infection (MOI) of 250 to
500 in culture medium for 16 hours. At this time, the
virus was removed by media replacement. Cell culture
media was collected 48 hours after the transfection
and 3H-thymidine (1.0 μCi/ml medium) was added.
Jurkat cells were incubated in this conditioned medium
for 48 hours. The incorporation of 3H-thymidine was
measured as described above.IL-2 ELISA assay
PHA and PMA activate T-lymphocytes and stimulate
production of IL-2 [15,16]. Jurkat cells were transiently
transfected with β-gal or murine Insl6 expression plas-
mids (pcDNA3, Invitrogen, Carlsbad, CA) as described
above. PHA and PMA were added into culture medium
24 hours after transfection. Supernatant was collected
48 hours post-transfection and IL-2 concentration was
measured by human IL-2 ELISA (Quantikine ELISA, R&D
Systems, Minneapolis, MN).Analysis in human myositis muscle biopsy samples
Skeletal muscle samples of polymyositis and dermatomyo-
sitis patients were collected by muscle biopsy at New
England Medical Center, St. Elizabeth Hospital and Tufts
University. The procedures were performed after obtain-
ing informed consent from all study subjects. The mean
time in storage at −80°C for control samples was 8.8 ±
0.9 years, compared to 8.1 ± 4.0 years for the polymyositis/
dermatomyositis samples. Insl6 mRNA levels were deter-
mined by real-time RT-PCR using an Applied Biosystems
(Woburn, MA) Model 7300 thermal cycler. Total RNA
was isolated from human fresh frozen skeletal muscles
(30 μg) using RNeasy mini kit or Trizol, following the
manufacturers’ instructions (Qiagen, Germantown, MD or
Invitrogen, Carlsbad, CA). RNA was reverse transcribed
using oligo dTand primers (50 μM each) and reverse tran-
scriptase (RT) (Multiscribe, 250 U) in the presence of
10 mM dNTP mixture in a total volume of 100 μl. First
strand cDNA and PCR reactions were generated with
equal amounts of starting material using the Applied
Biosystems (Woburn, MA) TaqMan Kit. Following de-
naturation at 95°C for 10 minutes, real-time PCR was
undertaken for 40 cycles of 95°C for 15 seconds and
60°C for 60 seconds. GAPDH was used as an internal con-
trol for quantification of relative expression of specific
transcripts. The sequences were as follows: human Insl6




of these muscle biopsy specimens from the polymyositis
and dermatomyositis patients were evaluated for the
degree of atrophy by a neuropathologist who was
blinded to the the level of Insl6 in the tissue. The 5, 10,
20, 25 values refer the percentage of myofibers that ap-
peared atrophic.
Statistical analysis
All values are presented as mean ± SEM. Student’s t-tests
were performed to assess the statistical significance of
two-way analyses. For multiple comparisons, analysis of
variance (ANOVA) was employed. P-values of less than
0.05 were considered statistically significant.
Results
Insl6 ablation impairs muscle regeneration
Previously, we reported that overexpression of Insl6 im-
proved the regenerative response of muscle to CTX injury
[8]. To further investigate the role of Insl6 in muscle re-
generation, we analyzed the response of Insl6-deficient
mice (Insl6-KO) in this model. Although no muscle ab-
normalities were observed in the unchallenged Insl6-KO
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were unaffected (data not shown), following CTX delivery
to the TA muscle these mice displayed an impaired regen-
erative response. More inflammatory cell infiltrate was ob-
served in H&E-stained histological sections, compared to
littermate wild-type mice (Figure 1a). Quantifying myofi-
ber area in these sections revealed that the regenerative
response was delayed in the Insl6-KO mice at both seven
and fourteen days following CTX delivery. Since muscle
injury with CTX elicits a T cell response [7], sections were
also stained for CD4 and CD8 cells. CTX-treated Insl6-
KO mice had increased CD4 and CD8 cells in injured
muscle compared to CTX-treated wild-type littermates
(Figure 1b). No CD4 or CD8 cells were observed in non-
injured muscles.WT
KO






Figure 1 Insl6-KO mice display impaired muscle regeneration in the m
CTX or equal volume of PBS was injected into to tibialis anterior (TA) musc
29-gauge needle. Representative images are H&E-stained TA muscle section
in histological sections by measuring the total myofiber cross-sectional are
wild-type control mice. (b) TA muscle sections at day 7 post-injury were st
CD8 antibody. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI)
under a fluorescent microscope with 40x objective lens. The results are presenInsl6-deficiency promotes experimental autoimmune
myositis severity
The consequences of Insl6-deficiency were evaluated in
a murine model of myositis, where a recombinant frag-
ment of human fast-type skeletal myosin-binding C pro-
tein was used as antigen in wild-type C57BL/6 female
mice [11]. In this model of C protein-induced myositis
(CIM), Insl6 protein levels were upregulated at 14 days
after immunization. Western blot analysis of gastrocne-
mius muscle (GA) revealed an approximate ten-fold up-
regulation of Insl6 compared with expression in muscle
from untreated control mice (Figure 2a). CIM also led to
an approximate three-fold increase in the expression of
the Insl6 transcript (Figure 2b). No Insl6 expression was
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odel of cardiotoxin (CTX) injury. (a) Ten micromolar solution of
le of Insl6-KO and wild-type mice at 2 μl/g body weight with a
s at day 7 and day 14 post-injury. Muscle regeneration was quantified
a. Data are expressed as a percentage relative to the mean value of
ained with either fluorescein isothiocyanate (FITC)-conjugated CD4 or
(blue). FITC-positive cells in 15 randomly selected fields were counted


















































































Figure 2 Insl6 muscle expression is increased in a murine model of myositis. Wild-type C57BL/6 female mice were immunized intradermally
with 600 μg recombinant human skeletal muscle myosin-binding protein C or an equal volume of PBS (control) emulsified with Freund’s adjuvant.
Two micrograms of pertussis toxin (PT) in PBS was injected intraperitoneally at the same time. (a) Gastrocnemius muscle from control and C
protein-induced myositis (CIM) mice were harvested 14 days after immunization and analyzed by Western blotting for Insl6 and tubulin-α, as a
loading control (left). The level of Insl6 was quantified relative to tubulin-α (right). (b) Transcript levels of Insl6 exon 1 and Neo cassette were
measured 14 days after CIM induction in wild-type mice and Insl6-KO mice. The results are presented as mean ± SEM. *P < 0.05, †P < 0.01.
Zeng et al. Skeletal Muscle 2014, 4:16 Page 6 of 14
http://www.skeletalmusclejournal.com/content/4/1/16KO mice have a Neo cassette inserted, expressed from
the mPGK1 promoter, to replace Insl6 exon1 [12]. This
Neo cassette could be detected in Insl6-KO mice but
not in wild-type mice (Figure 2b).
Muscle motor function was evaluated by the performance
on Rotarod and treadmill devices in the different experi-
mental groups. These physiological parameters did not
differ between wild-type and Insl6-KO mice at baseline
(Figure 3a). CIM conditions led to a running distance de-
cline of 70 to 80% in Insl6-KO mice, whereas wild-type
mice had only a 30 to 40% reduction. The CIM-induced
decline in Rotarod performance was highly notable in the
Insl6-KO versus wild-type mice (Additional file 1: Figure S1).
Under these test conditions, Insl6-deficiency led to an ap-
proximately 90% decline in performance but wild-type
mice showed an approximately 50% decline (Figure 3a).
Infiltration of CD4 and CD8 T cells in muscle is a hall-
mark of the CIM model [11]. Thus, CD4 and CD8 T cell
infiltration was assessed in multiple lower limb muscles,
including TA, GA, and quadriceps. No appreciable T cell
infiltration was observed in wild-type or Insl6-KO mice
at baseline (data not shown). The infiltration of CD4
and CD8 T cells was observed in most of the limb mus-
cles of the CIM mice. In Figure 3b, a representative
image of TA muscle section stained with CD4/CD8 and
laminin is shown. Quantitative analyses revealed more
CD4 and CD8 T cells present in the Insl6-KO muscle,compared with wild-type controls. T cell infiltration was
observed in the perimysial and perivascular areas. No
obvious endomysial CD8 T cell infiltration was observed
in any experimental condition, in contrast with a prior
report [11]. Analysis of histological sections of muscle
with the macrophage marker F4/80 showed a trend to-
ward greater infiltration of macrophages in the Insl6-KO
mice under CIM conditions, but this difference was not
statistically significant (Additional file 2: Figure S3).
Using RNA isolated from lower limb muscles, qRT-PCR
analyses were performed to measure the expression of in-
flammatory marker genes. Consistent with the histological
analyses in Figure 3b, CD4 and CD8 transcript levels were
elevated in Insl6-KO mice relative to wild-type in the CIM
model (Figure 3c). Transcript levels of inflammatory cyto-
kines TNF-α and IFN-γ were also significantly increased
in Insl6-KO versus wild-type mice in the CIM condition
(Figure 3d). At baseline, transcript levels of CD8, CD4,
TNF-α, and IFN-γ are very low in both Insl6-KO and
wild-type mice, and there was no difference between
groups.
Transgenic Insl6 overexpression ameliorates experimental
autoimmune myositis
Unchallenged Insl6-TG mice and wild-type littermates
displayed similar physical performance by Rotarod and
















































































































































































Figure 3 Insl6-deficiency exacerbates experimental autoimmune myositis. Myosin-binding C protein fragment, Freund’s adjuvant and
pertussis toxin (PT) were injected into homozygous Insl6-KO female mice and their wild-type littermates. (a) C protein-induced myositis (CIM) and
control mice were examined on treadmill and Rotarod tests before and 14 days after the immunization. For the treadmill evaluation, a starting
speed of six m/minute was set and increased by two m/minute every five minutes (left). The Rotarod test was performed at ten revolutions/minute
for knockout (KO) and littermate wild-type mice. Running ability and Rotarod score were measured as described in Methods. (b) Representative image
of tibialis anterior (TA) muscle sections stained with anti-CD4 and anti-CD8 eFluor® 650NC antibodies at day 14 after the immunization (left). The number
of CD8 or CD4 cells per field was counted in 15 randomly selected fields. Quantitative data are presented as CD8 or CD4 cells per high-powered
field (right). (c and d) Total RNA was isolated from lower limb muscles of control and CIM mice at post-immunized day 14, and cDNA was
synthesized. Relative transcript expression of CD4, CD8, TNF-α and IFN-γ was measured by qRT-PCR. The data were normalized by 36B4 (n = 8,
in each group). The results are presented as mean ± SEM. *P < 0.05, †P < 0.01.
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ning and balance performance. However, the impairment
occurred to a lesser extent in TG mice (Figure 4a). In the
treadmill text, the running distance was reduced by
80% in wild-type mice under CIM conditions, whereas
TG mice only showed a 40% reduction. In the Rotarod
test, TG mice were visibly more capable of staying on therotating cylinder longer than wild-type mice (Additional file 3:
Figure S2).
Analyses of limb muscle revealed that transgenic over-
expression of Insl6 diminished inflammation in the CIM
model. Muscle transcript levels of CD4, CD8, TNF-α
and IFN-γ increased in both wild-type and TG mice in

























































































































































Figure 4 Transgenic Insl6 over-expression ameliorates experimental autoimmune myositis. MCK-Insl6-TG female mice and wild-type
littermates were subjected to the C protein-induced myositis (CIM) protocol. (a) Mice were examined on treadmill (left) and Rotarod (right) before
and 14 days after the immunization. For the treadmill evaluation, a starting speed of ten m/minute was set and increased by five m/minute every
five minutes. The Rotarod test was performed at 20 revolutions/minute for transgenic (TG) mice and wild-type littermates. Running distance and
Rotarod score were measured as described in Methods. (b and c) Total RNA was isolated from lower limb muscles of control and CIM mice
14 days after immunization, and cDNA was synthesized. Relative transcript expression of CD4, CD8, TNF-α, and IFN-γ (n = 5 to 7 in each group)
was measured by qRT-PCR. The data were normalized by 36B4. The results are presented as mean ± SEM. *P < 0.05, †P < 0.01.
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mice (Figure 4b, c). However, analysis of histological sec-
tions of muscle with the marker F4/80 did not show a
difference in macrophage infiltration between wild-type
and TG mice (Additional file 2: Figure S3).
Hydrodynamic Insl6 gene delivery ameliorates
experimental autoimmune myositis
To test whether the acute expression of Insl6 is protect-
ive in the myositis model, we employed a hydrodynamic
model of Insl6 gene delivery. Hydrodynamic gene deliv-
ery involves the rapid injection of a relatively large vol-
ume of plasmid DNA solution via the tail vein, leadingto the transduction of liver and the production and se-
cretion of plasmid-encoded proteins [13]. This method
of acute gene delivery avoids the confounding aspects of
viral vectors, in particular the activation of a T cell in-
flammatory response [17]. Using hydrodynamic delivery,
a plasmid expressing Insl6 or an empty vector was deliv-
ered to Insl6-KO mice under non-CIM conditions at the
time of immunization with the C-protein fragment. This
procedure led to detectable levels of the Fc-Insl6 fusion
protein in the serum, with levels as high as 1,800 ng/ml
as measured by human Fc ELISA (not shown). Delivery
of the Insl6-expressing plasmid had no effect on baseline











































































































































Figure 5 Hydrodynamic Insl6 gene delivery improves myositis in Insl6-KO mice. Ten micrograms of Insl6-Fc or Fc control plasmid vectors
were dissolved in a large volume of saline and injected quickly via the tail vein as described in Methods. C protein-induced myositis (CIM) immunogens
were injected the next day. (a) Mice were examined on Rotarod before and 14 days after CIM induction. The Rotarod test was performed at 10
revolutions/minute and the score was determined as described in Methods. (b and c) Total RNA was isolated from lower limb muscles at
14 days after CIM induction and subjected to cDNA synthesis. Relative transcript expression of CD4, CD8, TNF-α, and IFN-γ (n = 6 in each group)
was measured by qRT-PCR. The data were normalized by 36B4. The results are presented as means ± SEM.
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provements in Rotarod performance in the CIM model.
Hydrodynamic delivery of Insl6 plasmid to CIM mice also
led to statistically significant reductions in transcript levels
of inflammatory marker proteins in TA muscle, including
CD4, CD8, TNF-α and IFN-γ, relative to muscle from ani-
mals that received the control vector (Figure 5b, c).
Insl6 inhibits Jurkat T cell activation
Jurkat cells, an immortalized line of human T lympho-
cytes, were used to probe the direct actions of Insl6 on T
cell signaling. Cells were transduced with Insl6 or β-galexpression vectors using an electroporation method. As
shown in Figure 6a, Insl6 overexpression significantly
inhibited Jurkat cell proliferation by approximately 40%
as measured by 3H-thymidine incorporation.
IL-2 signaling promotes proliferation, survival and
cytokine production in T cells [18]. Little or no IL-2 is
produced from Jurkat cells at baseline, but PHA- and
PMA-induced protein kinase C activation can robustly
stimulate IL-2 production [19]. As shown in Figure 6a,
Insl6 overexpression reduced the PMA/PHA-induced
IL-2 secretion by 40%. Since Insl6 is a secreted protein























































































Figure 6 Insl6 inhibits Jurkat cell proliferation and IL-2 secretion induced by phorbol 12-myristate 13-acetate/phytohemagglutinin
(PMA/PHA) stimulation. (a) Insl6 or β-gal encoding plasmid vectors were introduced into Jurkat T cells by electroporation. 3H-thymidine pulse
labeling was performed 48 hours after the transfection (left). Data are expressed as relative to the mean of the β-gal experimental group (left).
PMA (50 ng/ml) and PHA (1 μg/ml) were added to the culture medium 24 hours after the transfection. Cell culture medium was collected after
24 hours of PMA/PHA incubation. IL-2 concentration in the supernatant was determined by ELISA (right). (b) Differentiated C2C12 myotubes were
transduced with Ad-β-gal or Ad-Insl6. Conditioned medium was harvested 48 hours after adenovirus transfection. Jurkat cells were incubated with
this conditioned medium for 24 hours in the presence of 3H-thymidine. Incorporated 3H-thymidine was quantified. Results are presented
as mean ± SEM.
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Myogenic C2C12 cells were transduced with adenoviral
vectors expressing murine Insl6 [8] or a control vector
expressing β-gal. Cell culture medium was collected
48 hours post-transduction. mRNA was extracted from
C2C12 cell lysates and Insl6 transcript was measured
by quantitative RT-PCR to confirm the Insl6 overex-
pression (data not shown). Jurkat cells were incubated
with Insl6 conditioned medium for 24 hours, and cell
proliferation was measured by the amount of incorpo-
rated 3H-thymidine. As shown in Figure 6b, incubation
of cells with Insl6-conditioned media led to a signifi-
cant reduction in proliferation.
Reduced Insl6 expression in clinical inflammatory
myositis
The mRNA transcript level of Insl6 was assessed in hu-
man skeletal muscle biopsy samples from polymyositis
and dermatomyositis patients. The cases were identified
using published criteria [21]. None of the polymyositis/
dermatomyositis patients were receiving steroid therapy
at the time of biopsy. Disease severity was similar in thisseries of inflammatory myositis cases as judged by reduc-
tions in quantified mean myofiber diameter and histopath-
ology grading [22] compared to previous case series [23,24].
Control cases underwent biopsy for various symptoms but
no individuals had high creatine phosphokinase (CPK)
values and no abnormalities were found after extensive
microscopic review including a special histochemistry bat-
tery. Cases of inclusion body myositis were excluded from
this set. The control set had a mean age of 58.8 ± 40 (36 to
85) years at the time of biopsy, 6 male and 8 female. The
polymyositis/dermatomyositis set had a mean age of 53.6 ±
5.2 (22 to 78) years, 4 male and 9 female. Differences in
age, sex and time in storage were not significantly different
between control and myositis groups (Table 1 and data not
shown). Whereas transcript levels of Insl6 in control
muscle were fairly uniform, myositis patients displayed an
overall reduction in Insl6 transcript levels (P = 0.0378) and
the expression of Insl6 was more heterogeneous with some
patients exhibiting very low levels of this factor (Figure 7a).
Furthermore, histological sections from the patients were
scored for the degree of myofiber atrophy and then plotted
against Insl6 transcript levels that were above and below




(n = 13) P-value
Age, mean ± SEM 58.8 ± 4.0 (36 to 85) 53.6 ± 5.2 (22 to 78) 0.59
Male, % (n) 42.9 (6/14) 30.7 (4/13)
Female, % (n) 57.1 (8/14) 69.2 (9/13)
Insl6 relative transcript,
mean ± SEM 0.98 ± 0.17 0.50 ± 0.11 0.038
DM = dermatomyositis; PM = polymyositis.
P=0.0378
P=0.0464
Insl6 high  Insl6 low 
a
b
Figure 7 Insl6 mRNA levels are down-regulated in human
polymyositis/dermatomyositis patient skeletal muscle samples.
Human skeletal muscle biopsy samples were obtained from clinically
diagnosed polymyositis/dermatomyositis (PM/DM) patients (n = 13).
Non-myositis patient samples were used as a control (n = 14). The
age and gender were matched in two groups. Total RNA was
isolated and cDNA was synthesized. Relative transcript expression of
human Insl6 was measured by qRT-PCR. The data were normalized
by GAPDH. (a) Insl6 mRNA transcript levels are compared between
control group and PM/DM patients group. Control group: 0.9825 ±
0.1725 (mean ± SEM), values (minimum 0.2621, median 0.7743 and
maximum 2.402), PM/DM group: 0.5043 ± 0.1077 (mean ± SEM),
values (minimum 0.0011, median 0.5471 and maximum 1.361). (b)
Muscle atrophy was observed in tissue sections of PM/DM muscle
biopsy samples following Gomori’s trichrome staining. The samples
were rated based upon percentage atrophy of type 1 and type 2
fibers. PM/DM patients were divided into two groups based upon
their Insl6 mRNA levels, and classified as the Insl6-low group
(value≤median) and the Insl6-high group (value >median).
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relative to clinical severity was observed (Figure 7b).
Discussion
Insl6 is upregulated in injured muscle and it has been
reported that it has muscle-regenerative and anti-
inflammatory properties when overexpressed in the
cardiotoxin model of muscle injury [8]. In this report,
we demonstrate that mice lacking Insl6 display enhanced
muscle inflammation and impaired regeneration following
exposure to cardiotoxin. The present study also reports
that Insl6 is protective in a murine model resembling hu-
man inflammatory myopathy using genetically modified
mice either lacking or overexpressing Insl6. Furthermore,
it is shown that overexpression of an Fc-Insl6 hybrid pro-
tein following hydrodynamic plasmid delivery im-
proves overall muscle pathology in this model based
upon functional, histological and biochemical evidence.
These data support a therapeutic role for Insl6 in inflam-
matory myopathies where there is a high unmet need for
new therapies.
Experimental myositis has been induced previously in dif-
ferent species with a variety of agents. Here, we employed a
model of autoimmune myositis in C57BL/6 mice by admin-
istering a single immunization of recombinant human skel-
etal C-protein fragment emulsified in Freund’s adjuvant
with heat-inactivated M. butyricum [11]. The resulting
histopathologic abnormalities resembled some features of
human polymyositis including CD4+ and CD8+ T cell in-
filtration. In our analyses, CD4+ and CD8+ T cells were
observed in perivascular and perimysial areas, but no pro-
nounced myofiber invasion was observed. While there
was no apparent myofiber necrosis, we observed pro-
nounced muscle motor dysfunction in both Rotarod and
treadmill within two weeks of immunization. Deficiency
of Insl6 led to an increase in CD4 and CD8 T cell infil-
tration, increased inflammatory cytokine expression and
greater motor function impairment in the myositis model.
Conversely, overexpression of Insl6, either by chronic
overexpression in muscle or acute systemic overex-
pression, minimized T cell infiltration and cytokine ex-
pression in muscle and improved performance in the
Rotarod and treadmill tests.It is widely recognized that subsets of T cells play im-
portant roles in the development of the myositis pheno-
type [3,25-27]. In our study, Insl6 was shown to inhibit T
cell activation and IL-2 cytokine secretion. These effects
could be shown either by directly overexpressing Insl6
within Jurkat T cells or by treating these cells with Insl6-
conditioned media. In addition, Insl6 negatively regulated
Zeng et al. Skeletal Muscle 2014, 4:16 Page 12 of 14
http://www.skeletalmusclejournal.com/content/4/1/16the production of inflammatory cytokines in muscle.
Previously, we reported that Insl6 can act on myoblasts
to promote a regenerative response in muscle [8]. Thus,
it appears that Insl6 can act both on inflammatory and
muscle cells to control the response to injury in muscle.
Interestingly, Insl6 mRNA transcript levels are down-
regulated in human myositis biopsy samples, whereas
this factor is upregulated in the murine models of myo-
sitis and cardiotoxin injury. We speculate that Insl6 is
an endogenous immunosuppressant or immunosurveil-
lance factor. In animal injury models that are relatively
short-term, the release of Insl6 may function as a self-
protective mechanism that minimizes immune-mediated
tissue destruction. However, in chronic human disease,
the reduction of Insl6 by an as-yet-unidentified mechan-
ism may contribute to the development of idiopathic in-
flammatory myopathies or other autoimmune diseases.
Consistent with this notion, low levels of Insl6 correlated
with disease severity. Thus, reestablishing the normal
upregulation of Insl6 in muscle of myositis patients may
have therapeutic utility.
Comparative genomic analysis shows that Insl6 is a
member of the insulin-like/relaxin family of proteins
that have diverse roles in reparative and reproductive
processes [28]. Whereas insulin-like growth factor (IGF)
and insulin activate tyrosine kinase receptors, most
insulin-like family proteins signal through G-protein-
coupled-receptors to control cAMP-mediated signaling
events [29]. However, the receptor for Insl6 has yet to be
identified, and nothing is known about the downstream
signaling molecules that respond to this ligand. Related
family members, including Insl1 (which is also referred
to as relaxin), have been shown to have both muscle-
and cardiovascular-protective actions. It has previously
been shown that relaxin will promote muscle repair in a
laceration model through its ability to diminish fibrosis
and promote satellite cell mobilization in both young
and aged mice [30,31]. Human recombinant relaxin-2
protein (RLX030) is in clinical development for the
treatment of acute heart failure [32]. In the RELAX-AHF
phase III clinical trial, patients treated with relaxin-2 for
48 hours experienced improved heart failure symptoms
and a 37% reduction in mortality, leading to a break-
through therapy designation by the Food and Drugs Ad-
ministration (FDA). Finally, Insl3 has been shown to
have cardiac regenerative properties in a zebrafish model
[33]. Thus the insulin-like/relaxin family members repre-
sent a potentially interesting source of factors for the
treatment of heart failure and muscle weakness, two
processes that are inter-related in the pathological con-
dition that is referred to as cardiac cachexia.
In contrast to the well-described anabolic functions of
the IGF isoforms [34,35], Insl6 overexpression neither
stimulates myogenesis in normal muscle nor inducesC2C12 cell hypertrophy in culture [8]. Insl6 promotes
muscle regeneration only after injury, and this effect is
associated with an increase in satellite cell activation
and the diminution of inflammatory marker expression
[8]. Consistent with these observations, the Insl6-deficient
mice generated by Burnicka-Turek and colleagues [12]
have morphologically and functionally normal muscle at
baseline. However, after muscle stress or damage, signifi-
cantly impaired regeneration and deteriorated pathology
were observed in the Insl6-deficient animals.
Many of the immunopathogenic processes behind
myositis remain poorly understood. However, it is gener-
ally accepted that cytokines and chemokines are essential
regulators of leukocyte activation and migration [3,11,36].
In animal EAM models, it has been reported that IL-6 or
IL-1 blockade diminishes the severity of myositis [37].
Regulatory T cells (Tregs) have been identified as a pivotal
cell population in the control of autoimmunity [38]. Treg-
deficiency causes over-proliferation of lymphocytes and
multi-organ autoimmunity in both humans and mice. Treg
abundance is significantly reduced in skin lesions and per-
ipheral blood of patients with dermatomyositis [39]. In
Treg-depleted mice, a more severe phenotype was ob-
served in the experimental autoimmune myositis model,
whereas the injection of Tregs at the time of immunization
significantly improved the disease [25].
To date, evidence for the utility of Insl6 as a potential
therapy for inflammatory myositis has been limited to
experimental settings using genetic models and plasmid-
driven overexpression in vivo. Future studies will involve
the development of a well-characterized, biologically-active
recombinant form of Insl6 to assess the pharmacological
activity of this protein and further elucidate its mechanism
of action.
Conclusions
Using mouse genetic models of Insl6-deficiency and over-
expression, this study has identified a role for Insl6 in ex-
perimental autoimmune myositis. Insl6 improves skeletal
muscle function and reduces inflammation in this murine
model. In vitro studies revealed that Insl6 inhibits T cell
proliferation and activation. Alterations in Insl6 expression
in samples taken from both human and murine myositis-
affected muscle highlight the potential for translational
impact. Further investigation into the anti-inflammatory
and muscle regenerative pathways mediated by Insl6 is
warranted.
Additional files
Additional file 1: Figure S1. Video of Rotarod evaluation of
experimental autoimmune myositis in Insl6 homozygous (KO) mice
versus wild-type (WT) littermates. Mice were immunized with recombinant
human skeletal muscle C protein as described in the CIM methods. Balance
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http://www.skeletalmusclejournal.com/content/4/1/16and coordination were evaluated with the Rotarod device 14 days after CIM
induction. The Rotarod test was performed by measuring time until the
mouse fell off the rod. The detailed protocol and scoring method are
described in the Methods.
Additional file 2: Figure S3. Macrophage infiltration to TA muscle in
experimental autoimmune myositis. Representative image of TA muscle
sections stained with antibodies of anti-F4/80 (secondary antibody: Alexa
Fluor594®) and anti-WGA-Alexa Fluor 498® at day 14 after the
immunization. The number of F4/80 positive cells per field was counted
in five randomly selected fields in each mouse. Quantitative data are
presented as F4/80 positive cells per field at x40 magnifying power
(KO: n = 3, WT: n = 3, lower left), (WT: n = 4, TG: n = 3, lower right).
Additional file 3: Figure S2. Video of Rotarod evaluation of
experimental autoimmune myositis in MCK-Insl6-TG versus wild-type (WT)
littermates. Details are as in Additional file 1: Figure S1 and Methods
sections.
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